Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) will report first quarter 2026 financial results on Tuesday, May 12, 2026.

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS) will report first quarter 2026 financial results on Tuesday, May 12, 2026. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Investors must register in advance to receive dial-in numbers and PIN; the webcast and an archived audio recording will be available on the company's Investors website for at least 30 days.

Argus May 6 session

+1.98% close to close Open Argus

Details

News Market Reaction – ABOS

In the May 6 session, ABOS gained 1.98%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules Acumen’s Q1 2026 results call for May 12, 2026 at 8:00 a.m. ET, continui...

Analysis

This announcement schedules Acumen’s Q1 2026 results call for May 12, 2026 at 8:00 a.m. ET, continuing its pattern of advance earnings-date disclosures. Context includes an active recent period of Alzheimer’s program updates, a March 2026 private placement, and an effective S-3 registering 10,833,331 resale shares. With the stock at $2.48, above its $2.08 200-day MA yet below the $3.60 52-week high, upcoming financial and clinical commentary will be a key focus.

Key Figures

Share price: $2.48 Daily price change: 4.2% Today’s volume: 310,523 shares +5 more

Share price

$2.48

Pre-announcement price on earnings-date news

Daily price change

4.2%

Change over prior 24 hours before this news

Today’s volume

310,523 shares

Vs 20-day average 359,432 shares

52-week range

$0.9586 – $3.60

Price 158.71% above low, 31.11% below high

200-day MA

$2.08

Price trading above long-term average

Registered resale shares

10,833,331 shares

Resale of private placement shares under S-3 shelf

Earnings call time

8:00 a.m. ET

Q1 2026 business and financial update on May 12, 2026

Webcast archive period

30 days

Archived in Investors section of company website

Previous Earnings date Reports

1 past event · Latest: Mar 19

Same Type 1 event

1. Mar 19

   Earnings date set

   24h Move

   -8.6%

   Announced Q4 and full-year 2025 earnings release date and webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clinical-stage biopharmaceutical, amyloid beta oligomers, Alzheimer’s disease, webcast

4 terms

clinical-stage biopharmaceutical medical

"a clinical-stage biopharmaceutical company developing novel therapeutics"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

amyloid beta oligomers medical

"target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s"

Small, soluble clumps of a brain protein called amyloid beta that can interfere with nerve cell function and are suspected to drive memory loss in neurodegenerative disease. Investors watch them because drugs that reduce or neutralize these oligomers are a major focus of research, and convincing evidence that a treatment affects them can sway clinical trial success, regulatory decisions and a company’s valuation — like finding the right lock-and-key to stop engine damage.

Alzheimer’s disease medical

"for the treatment of Alzheimer’s disease, today announced that the Company"

A progressive brain disorder that gradually erodes memory, thinking and the ability to perform everyday tasks, similar to a computer slowly losing files and processing speed. It matters to investors because its large and growing patient population drives demand for treatments, long-term care, diagnostics and related services, making clinical trial results, regulatory decisions and patent exclusivity major value drivers for healthcare and biotech companies.

webcast technical

"The Company will host a conference call and live audio webcast at 8:00 a.m."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter financial results on Tuesday, May 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.  

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.    

The webcast audio will be available via this link.

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE^® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media:  

ICR Healthcare 
AcumenPR@icrhealthcare.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Acumen Pharmaceuticals (ABOS) report Q1 2026 results?

Acumen will report Q1 2026 results on Tuesday, May 12, 2026 with a conference call at 8:00 a.m. ET. According to the company, the event will include a business and financial update and a live audio webcast for investors.

How can I join the Acumen (ABOS) May 12, 2026 conference call?

You must register in advance to join the May 12, 2026 call and receive dial-in numbers and a PIN. According to the company, registration details are provided via the links the company published for the event.

Will Acumen (ABOS) provide a webcast or recording of the May 12, 2026 update?

Yes, Acumen will provide a live audio webcast of the May 12, 2026 update and an archived version afterward. According to the company, the archived audio will be available on the Investors section of its website for at least 30 days.

What time is Acumen Pharmaceuticals (ABOS) investor call on May 12, 2026?

The investor call is scheduled for 8:00 a.m. ET on May 12, 2026. According to the company, the call will cover both business and financial updates and will be accessible via live webcast.

Where can I find the archived Acumen (ABOS) webcast after the May 12, 2026 event?

The archived webcast will be posted in the Investors section of Acumen's website for at least 30 days after the event. According to the company, the archive will be accessible at www.acumenpharm.com.